Management commentary

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The clinical models presented by Parker (Chapter 17) and by Ketter and Wang (Chapter 18) are comprehensive, timely, and are a good example of the necessity in evaluating the evidence base (in this case being somewhat limited in relation to Bipolar II disorder or BP II) in juxtaposition with practitioners’ experience in optimising treatment selection. From the standpoint of diagnostic criteria, I look forward to evaluating how these criteria may change, with DSM-V Field Trials for bipolar disorder currently under way. There is increasing recognition of the phenomenological concept of mixed presentations. If DSM-V does change these criteria, it will most assuredly impact on treatment considerations for BP II. The impact would be even greater if the 4-day criterion is waived for hypomania. Such changes would include many current ‘soft bipolar’ conditions into the BP II domain – conditions which have been minimally studied in terms of clinical treatment.

Original languageEnglish (US)
Title of host publicationBipolar II Disorder: Modelling, Measuring and Managing, Second Edition
PublisherCambridge University Press
Pages228-230
Number of pages3
ISBN (Print)9781139003315, 9781107600898
DOIs
StatePublished - Jan 1 2012

Fingerprint

Bipolar Disorder
Diagnostic and Statistical Manual of Mental Disorders

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Frye, M. A. (2012). Management commentary. In Bipolar II Disorder: Modelling, Measuring and Managing, Second Edition (pp. 228-230). Cambridge University Press. https://doi.org/10.1017/CBO9781139003315.023

Management commentary. / Frye, Mark A.

Bipolar II Disorder: Modelling, Measuring and Managing, Second Edition. Cambridge University Press, 2012. p. 228-230.

Research output: Chapter in Book/Report/Conference proceedingChapter

Frye, MA 2012, Management commentary. in Bipolar II Disorder: Modelling, Measuring and Managing, Second Edition. Cambridge University Press, pp. 228-230. https://doi.org/10.1017/CBO9781139003315.023
Frye MA. Management commentary. In Bipolar II Disorder: Modelling, Measuring and Managing, Second Edition. Cambridge University Press. 2012. p. 228-230 https://doi.org/10.1017/CBO9781139003315.023
Frye, Mark A. / Management commentary. Bipolar II Disorder: Modelling, Measuring and Managing, Second Edition. Cambridge University Press, 2012. pp. 228-230
@inbook{906820bdcf204364963067697d084061,
title = "Management commentary",
abstract = "The clinical models presented by Parker (Chapter 17) and by Ketter and Wang (Chapter 18) are comprehensive, timely, and are a good example of the necessity in evaluating the evidence base (in this case being somewhat limited in relation to Bipolar II disorder or BP II) in juxtaposition with practitioners’ experience in optimising treatment selection. From the standpoint of diagnostic criteria, I look forward to evaluating how these criteria may change, with DSM-V Field Trials for bipolar disorder currently under way. There is increasing recognition of the phenomenological concept of mixed presentations. If DSM-V does change these criteria, it will most assuredly impact on treatment considerations for BP II. The impact would be even greater if the 4-day criterion is waived for hypomania. Such changes would include many current ‘soft bipolar’ conditions into the BP II domain – conditions which have been minimally studied in terms of clinical treatment.",
author = "Frye, {Mark A}",
year = "2012",
month = "1",
day = "1",
doi = "10.1017/CBO9781139003315.023",
language = "English (US)",
isbn = "9781139003315",
pages = "228--230",
booktitle = "Bipolar II Disorder: Modelling, Measuring and Managing, Second Edition",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Management commentary

AU - Frye, Mark A

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The clinical models presented by Parker (Chapter 17) and by Ketter and Wang (Chapter 18) are comprehensive, timely, and are a good example of the necessity in evaluating the evidence base (in this case being somewhat limited in relation to Bipolar II disorder or BP II) in juxtaposition with practitioners’ experience in optimising treatment selection. From the standpoint of diagnostic criteria, I look forward to evaluating how these criteria may change, with DSM-V Field Trials for bipolar disorder currently under way. There is increasing recognition of the phenomenological concept of mixed presentations. If DSM-V does change these criteria, it will most assuredly impact on treatment considerations for BP II. The impact would be even greater if the 4-day criterion is waived for hypomania. Such changes would include many current ‘soft bipolar’ conditions into the BP II domain – conditions which have been minimally studied in terms of clinical treatment.

AB - The clinical models presented by Parker (Chapter 17) and by Ketter and Wang (Chapter 18) are comprehensive, timely, and are a good example of the necessity in evaluating the evidence base (in this case being somewhat limited in relation to Bipolar II disorder or BP II) in juxtaposition with practitioners’ experience in optimising treatment selection. From the standpoint of diagnostic criteria, I look forward to evaluating how these criteria may change, with DSM-V Field Trials for bipolar disorder currently under way. There is increasing recognition of the phenomenological concept of mixed presentations. If DSM-V does change these criteria, it will most assuredly impact on treatment considerations for BP II. The impact would be even greater if the 4-day criterion is waived for hypomania. Such changes would include many current ‘soft bipolar’ conditions into the BP II domain – conditions which have been minimally studied in terms of clinical treatment.

UR - http://www.scopus.com/inward/record.url?scp=84925679918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925679918&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139003315.023

DO - 10.1017/CBO9781139003315.023

M3 - Chapter

AN - SCOPUS:84925679918

SN - 9781139003315

SN - 9781107600898

SP - 228

EP - 230

BT - Bipolar II Disorder: Modelling, Measuring and Managing, Second Edition

PB - Cambridge University Press

ER -